Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen

Condition:   SCCHN
Interventions:   Drug: NC-6004;   Drug: Pembrolizumab
Sponsors:   NanoCarrier Co., Ltd.;   Orient Europharma Co., Ltd.
Not yet recruiting

https://ift.tt/2zQW0e8